



A Carelon Company

# ACTEMRA (TOCILIZUMAB) INFUSION ORDERS

**P:** 877-365-5566 | **F:** 855-889-2946

## PATIENT INFORMATION

Fax completed form, insurance information, and clinical documentation to 855-889-2946

Name:		DOB:	Gender: <input type="checkbox"/> Female <input type="checkbox"/> Male	
Address:		City:	State:	ZIP:
Phone:	Email:	Height:	<input type="checkbox"/> inches <input type="checkbox"/> cm	Weight: <input type="checkbox"/> lbs. <input type="checkbox"/> kg

Allergies:

<b>Diagnosis Code ICD-10 (required):</b>	<b>Diagnosis Description:</b>
Patient Status: <input type="checkbox"/> New to Therapy <input type="checkbox"/> Continuing Therapy	Next Treatment Date:

## PHYSICIAN INFORMATION

Prescriber Name:	Phone:	Fax:
Office Contact:	Email:	
Address:	City:	State: ZIP:
NPI #:	DEA#:	Tax ID:

## INSURANCE INFORMATION (or attach copy of cards)

Primary Insurance:	Policy #:	Group #:
Secondary Insurance:	Policy #:	Group #:

## PRESCRIPTION INFORMATION (or attach a copy of the prescription)

Drug	Dosing	Refills
<b>Actemra</b> (tocilizumab)	<input type="checkbox"/> 4mg/kg IV every 4 weeks for _____ doses, followed by 8 mg/kg IV every 4 weeks thereafter <input type="checkbox"/> 4mg/kg IV every 4 weeks <input type="checkbox"/> 8mg/kg IV every 4 weeks <input type="checkbox"/> _____ mg IV every 4 weeks <input type="checkbox"/> Other: _____	*DOSE NOT TO EXCEED 600MG IN GCA DX *DOSE NOT TO EXCEED 800MG IN RA/CRS DX <input type="checkbox"/> x 1 year <input type="checkbox"/> _____

### Lab Protocol:

**All dx:** Obtain CBC w/diff, LFTs, & Lipid Panel prior to 1st infusion

**RA/GCA:** CBC w/diff, LFTs, & Lipid Panel prior to 3rd infusion

All subsequent infusions - CBC w/diff q 3 months; LFTs q 4-8 weeks for 1st 6 months, then q 3 months

**PJIA:** CBC w/diff, LFTs, & Lipid Panel prior to 2nd dose; then CBC w/diff & LFTs q 4-8 weeks

**SJIA:** CBC w/diff & LFTs prior to 2nd dose; Lipid Panel between 4-8 weeks; then CBC w/diff & LFTs q 2-4 weeks

Additional Lab Orders: \_\_\_\_\_ Frequency: \_\_\_\_\_

TB QFT Screening yearly (optional)  Baseline HepBcAB total

Required labs to be drawn by:  Paragon  Referring Provider

Other orders: \_\_\_\_\_

As required by your state, Prescriber to check "Dispense as written" or handwritten "Brand Medically Necessary" and sign to prevent generic substitution.  Dispense as written

**PRESCRIBER SIGNATURE** By signing this form and utilizing our services, you are authorizing Paragon Healthcare, Inc. and its employees to serve as your prior authorization and specialty pharmacy designated agent in dealing with medical and prescription insurance companies, and to select the preferred site of care for the patient.

**Prescriber Signature: X**

**Date:**

**PATIENT INFORMATION**

Name:

DOB:

**REQUIRED DOCUMENTATION FOR REFERRAL PROCESSING & INSURANCE APPROVAL**

- Include signed and completed order (MD/prescriber to complete page 1)
- Include patient demographic information and insurance information
- Include patient's medication list
- Supporting clinical notes to include any past tried and/or failed therapies, intolerance, benefits, or contraindications to conventional therapy
  - Rheum - Has the patient had a documented contraindication/intolerance or failed trial of a DMARD, NSAID, or conventional therapy (i.e., MTX, leflunomide)?  Yes  No  
If yes, which drug(s)? \_\_\_\_\_
  - Rheum - Does the patient have a contraindication/intolerance or failed trial to at least one biologic (i.e., Humira, Simponi, Xeljanz, infliximab)?  Yes  No  
If yes, which drug(s)? \_\_\_\_\_
  - CRS dx - Has the patient received treatment with a chimeric antigen receptor T cell therapy (i.e., Kymriah, Yescarta) or Blincyto?  Yes  No If yes, which drug(s)? \_\_\_\_\_
- Include labs and/or test results to support diagnosis
  - Rheumatoid Factor or anti-CCP (attach results)
  - Temporal artery biopsy or cross-sectional imaging or acute-phase reactant elevation (GCA dx)
- If applicable* - Last known biological therapy: \_\_\_\_\_ and last date received: \_\_\_\_\_.  
If patient is switching to biologic therapies, please perform a wash-out period of \_\_\_\_\_ weeks prior to starting Actemra.
- Other medical necessity: \_\_\_\_\_

**REQUIRED PRE-SCREENING**

- TB screening test (completed within 12 months if a new start) - attach results**
  - Positive  Negative
- Hepatitis B screening test completed (Hepatitis B surface antigen) - attach results**
  - Positive  Negative
- CBC w/diff, LFTs, Lipid Panel - attach results**

\*If TB or Hepatitis B results are positive - please provide documentation of treatment or medical clearance, and a negative CXR (TB+)